{"id":"humalog-mix-75-25","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This product contains 75% insulin lispro protamine suspension (intermediate-acting) and 25% insulin lispro (rapid-acting). The rapid-acting component begins working within 15 minutes to address postprandial glucose spikes, while the intermediate-acting component provides basal coverage over several hours. Together, they mimic a more physiologic insulin secretion pattern in patients with type 1 or type 2 diabetes.","oneSentence":"Humalog Mix 75/25 is a combination insulin product that provides both rapid-acting and intermediate-acting insulin to control blood glucose levels in diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:45.663Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04023344","phase":"PHASE3","title":"Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Geropharm","startDate":"2018-03-14","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":210},{"nctId":"NCT03320031","phase":"PHASE4","title":"A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy","status":"UNKNOWN","sponsor":"Yanbing Li","startDate":"2017-06-03","conditions":"Type 2 Diabetes Mellitus, Peritoneal Dialysis","enrollment":232},{"nctId":"NCT02446028","phase":"PHASE2","title":"A Study Evaluating Safety and Efficacy of BIOD 531 Compared to Humalog® Mix 75/25 in Subjects With Type 2 Diabetes","status":"SUSPENDED","sponsor":"Biodel","startDate":"2015-05","conditions":"Diabetes Mellitus","enrollment":13},{"nctId":"NCT02212951","phase":"PHASE1, PHASE2","title":"Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500","status":"COMPLETED","sponsor":"Biodel","startDate":"2014-05","conditions":"Type 2 Diabetes Mellitus","enrollment":12},{"nctId":"NCT02324309","phase":"PHASE1, PHASE2","title":"BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance","status":"COMPLETED","sponsor":"Biodel","startDate":"2014-05","conditions":"Diabetes Mellitus","enrollment":12},{"nctId":"NCT02514850","phase":"PHASE1","title":"A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Adocia","startDate":"2015-07","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT01773473","phase":"PHASE4","title":"Comparison of Insulin Mix25 Versus Mix50","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-01","conditions":"Type 2 Diabetes Mellitus","enrollment":403},{"nctId":"NCT01175824","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-04","conditions":"Diabetes Mellitus, Type 2","enrollment":478},{"nctId":"NCT01175811","phase":"PHASE4","title":"A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-02","conditions":"Diabetes Mellitus, Type 2","enrollment":402},{"nctId":"NCT01398670","phase":"PHASE3","title":"Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics","status":"WITHDRAWN","sponsor":"Wockhardt","startDate":"2012-02","conditions":"Type I Diabetes","enrollment":""},{"nctId":"NCT01400802","phase":"PHASE1","title":"Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Mixture Listro Mix 75/25® and Humalog Mix75/25 ® in Healthy Subjects","status":"WITHDRAWN","sponsor":"Wockhardt","startDate":"2011-11","conditions":"Bioequivalence in Healthy Subjects","enrollment":""},{"nctId":"NCT01336751","phase":"PHASE3","title":"Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-07","conditions":"Diabetes Mellitus, Type 2","enrollment":212},{"nctId":"NCT01303042","phase":"NA","title":"Efficacy of Insulin Lispro Mix 50/50 Therapy","status":"UNKNOWN","sponsor":"Aichi Gakuin University","startDate":"2011-02","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT00279201","phase":"PHASE4","title":"The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-12","conditions":"Diabetes Mellitus, Type 2","enrollment":2091},{"nctId":"NCT00551538","phase":"PHASE4","title":"24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-05","conditions":"Type 2 Diabetes","enrollment":15},{"nctId":"NCT00135941","phase":"PHASE3","title":"Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-08","conditions":"Diabetes Mellitus","enrollment":582},{"nctId":"NCT00551356","phase":"PHASE3","title":"Lispro Mix 25 vs. Glargine in Type 2 Diabetics","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-11","conditions":"Diabetes Mellitus Type 2","enrollment":53}],"_emaApprovals":[],"_faersSignals":[{"count":516,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":211,"reaction":"BLOOD GLUCOSE DECREASED"},{"count":125,"reaction":"PHARMACEUTICAL PRODUCT COMPLAINT"},{"count":113,"reaction":"FALL"},{"count":108,"reaction":"HYPOGLYCAEMIA"},{"count":102,"reaction":"DRUG INEFFECTIVE"},{"count":82,"reaction":"NAUSEA"},{"count":81,"reaction":"MALAISE"},{"count":80,"reaction":"WEIGHT DECREASED"},{"count":79,"reaction":"VISUAL ACUITY REDUCED"}],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["insulin lispro 75/25"],"phase":"marketed","status":"active","brandName":"Humalog Mix 75/25","genericName":"Humalog Mix 75/25","companyName":"Biodel","companyId":"biodel","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Humalog Mix 75/25 is a combination insulin product that provides both rapid-acting and intermediate-acting insulin to control blood glucose levels in diabetes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}